

Mechanisms of Resistance to Checkpoint Blockade

Julie R. Brahmer, MD, MSc Professor of Oncology Johns Hopkins Kimmel Cancer Center Baltimore, MD





Personal financial interests

•Advisory board: AstraZeneca, Janssen, Syndax, Genentech, BMS, Merck, Eli Lilly, Celgene, Amgen

•Grant funding: BMS

Institutional financial interests

•Clinical trial: Incyte, BMS, MedImmune/AstraZeneca, Janssen, FLXBio




Types of Resistance

- Primary Resistance No response
- Acquired Resistance Progression of disease post response typically defined as progression after 6 months of therapy





Primary Resistance Mechanisms to Checkpoint Blockade




Adapted from Zitvogel L et al Immunity Review 2016

#SITC2019



Non-inflamed Tumors "COLD" versus Inflamed "HOT" Tumors



34th Annual Meeting & Pre-Conference Programs




Chen D and Mellman I, Nature 2017



Host Factors Influencing Response/Resistance HLA

• Homozygosity of HLA-B, HLA-A, HLA-DP, and HLA-DPB alleles are associated with poor OS




• HLA-B62 associated with poor OS

Chowell D et al Science 2018



Host Factors: Microbiome and Immunotherapy for Cancer

Host factors such as the human microbiome may augment responses to immune checkpoint agents for cancer




Metastatic melanoma, PD-1 (n=45)

Gopalakrishnan et al, Science 2017



Host Factors: Microbiome and Immunotherapy In NSCLC

- Microbiota implicated in response may differ by tumor type
- Response may be modulated by prior antibiotic use
- NSCLC (n=60), RCC (n=40) validation cohort NSCLC (n=27), RCC (n=26)
- Beneficial (PFS at 3 months)
- Richness
- s_Akkermansia mucinophila
- s_Enterococcus hirae
- Detrimental (PFS at 3 months)
- Antibiotics











Tumor-Intrinsic Factors Influencing Response to Checkpoint Blockade

Tumor Mutation Load






- NDB No durable benefit
- MSI
- Mutations in DNA repair genes-MLH1, MSH2, BRCA2, POLD1, POLE

Rizvi NA, et al. *Science*. 2015;348:124-128 Peters S et al AACR 2017 Le D et al Science 2017 Borcherding N et al J Mol Biol 2018





- Jak 1 and 2 mutations Examples from melanoma, colon cancer, NSCLC
- Major relays in INF-γ signaling
- PD-L1 expression is mediated via activation of JAK/STAT





Shin DS et al Cancer Discovery 2016 Riaz N et al Nat Genet 2016 Zaretsky JM, et al NEJM 2016



#SITC2019

• STK11 in KRAS mutated lung cancers





Lack of PD-L1 expression Upregulation of MYC = decreased T cell infiltrate

Skoulidis F et al Cancer Discov 2018


34th Annual Meeting & Pre-Conference Programs



#SITC2019

Durvalumab vs chemotherapy

STK11 mutated lung cancers – lessons from PD-L1 and PD-L1 and CTLA-4 combination



Durvalumab + tremelimumab vs chemotherapy




Rizvi N et al WCLC 2019



KEAP1 mutated lung cancers – lessons from PD-L1 and PD-L1 and CTLA-4 combination

Durvalumab vs chemotherapy

Durvalumab + tremelimumab vs chemotherapy



Primary Resistance: Tumor Intrinsic

- PTEN deletion upregulation if immune suppressive cytokines associated with reduced T-cell infiltration and increased immune suppressive cells in the TME.
- WNT-β-catenin signaling upregulation decreased recruitment of T cells via downregulation of CCL4
- Epithelial-mesenchymal transition (EMT) gene expression signatures associated with innate resistance to PD-1 blockade

Liu D et al Amer J Clin Derm 2019





Acquired Resistance

- Selection pressure to reduce mutational load
- Mutations of copy number alterations in Type 1 and Type 2 INF limiting immune activation in the TME
- Other checkpoint upregulation TIM-3


Riaz N et al Cell 2017, Zaretsky JM NEJM 2016, Gao J et al Cell 2016, Koyama S et al Nat Commun 2016



Acquired Resistance:

Mechanisms of Neoantigen Loss in Resistant Tumors

C sitc



Two mechanisms of neoantigen loss


- The first is through the immune elimination of neoantigen-containing tumor cells that represent a subset of the tumor cell population, followed by subsequent outgrowth of the remaining cells.
- The second is through the acquisition of one or more genetic events in a tumor cell that results in neoantigen loss, followed by selection and expansion of the resistant clone.

Slide provided by Dr. Anagnostou

#SILC2019

Anagnostou, Smith et al Cancer Discovery, 2017 34th Annual Meeting & Pre-Conference Programs

Acquired Resistance: B2-microglobulin loss/HLA Class 1 Antigen Processing




Gettinger S Cancer Discovery 2017





Acquired Resistance: Class 1 HLA Loss



If transcriptional loss, then hypomethylating agents may upregulate Class 1 HLA again.


Paulson KG et al Nature Comm 2018

#SITC2019



Acquired Resistance: Upregulation of Checkpoint Pathways

- LAG3
- TIGIT
- PD-L2
- CTLA4
- VISTA
- TIM-3




Gettinger S Cancer Discovery 2017

#SITC2019





Acquired Resistance: Upregulation of Checkpoint Pathways – TIM-3




Koyama S et al Nat Com 2015






Acquired Resistance: Upregulation of Checkpoint Pathways – TIM-3



Koyama S et al Nat Com 2015








Slide adapted from Scott Gettinger ASCO-SITC 2018




#SITC2019









Slide adapted from Scott Gettinger ASCO-SITC 2018



Just the tip of the iceberg......







Johns Hopkins Bloomberg-Kimmel Institute For Cancer Immunotherapy





